Omeros (NASDAQ:OMER) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday, BidAskClub reports.

A number of other analysts also recently weighed in on OMER. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Omeros in a report on Tuesday, May 12th. Wedbush restated a “hold” rating and issued a $17.00 target price on shares of Omeros in a report on Tuesday, June 9th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Tuesday, May 12th. Finally, Zacks Investment Research upgraded shares of Omeros from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Omeros currently has a consensus rating of “Hold” and an average price target of $22.75.

Shares of OMER traded down $0.82 on Friday, hitting $12.83. 632,307 shares of the stock traded hands, compared to its average volume of 303,456. The company has a market capitalization of $699.36 million, a PE ratio of -7.42 and a beta of 1.86. The business has a 50 day simple moving average of $14.53 and a 200 day simple moving average of $14.13. Omeros has a one year low of $8.50 and a one year high of $20.92.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.19). The company had revenue of $23.54 million for the quarter, compared to the consensus estimate of $30.92 million. On average, equities research analysts forecast that Omeros will post -1.77 earnings per share for the current year.

In related news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $14.40, for a total value of $72,000.00. Following the completion of the transaction, the director now owns 40,067 shares in the company, valued at $576,964.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.30% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. State Street Corp increased its stake in Omeros by 4.9% in the 1st quarter. State Street Corp now owns 1,161,905 shares of the biopharmaceutical company’s stock valued at $15,535,000 after buying an additional 53,885 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of Omeros by 10.9% during the 1st quarter. Nuveen Asset Management LLC now owns 221,640 shares of the biopharmaceutical company’s stock worth $2,963,000 after acquiring an additional 21,821 shares during the period. Balyasny Asset Management LLC purchased a new position in shares of Omeros during the 1st quarter worth about $434,000. American International Group Inc. increased its position in Omeros by 2.5% during the 1st quarter. American International Group Inc. now owns 30,285 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 727 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Omeros by 17.8% during the 1st quarter. Wells Fargo & Company MN now owns 105,023 shares of the biopharmaceutical company’s stock worth $1,404,000 after purchasing an additional 15,875 shares in the last quarter. Institutional investors and hedge funds own 57.42% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Marijuana Stocks Investing Considerations

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.